BIODESIX INC
For the period ended Aug 5, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 5, 2026 · Filed Aug 5, 2026
Use the contents to explore the available documents and sections.
BDSX$8.53-57.0%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (in thousands, except per share data)
(in thousands, except per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenues | ||||
| Diagnostic Tests | $25,349 | $17,898 | $47,640 | $34,214 |
| Development Services | 1,512 | 2,120 | 4,776 | 3,762 |
| Total revenues | 26,861 | 20,018 | 52,416 | 37,976 |
| Direct costs and expenses | 4,820 | 4,031 | 9,025 | 7,734 |
| Research and development | 3,135 | 3,269 | 6,420 | 6,139 |
| Sales, marketing, general and administrative | 24,282 | 22,411 | 48,543 | 42,859 |
| Impairment loss on intangible assets | 12 | 26 | 17 | 99 |
| Total operating expenses | 32,249 | 29,737 | 64,005 | 56,831 |
| Loss from operations | (5,388) | (9,719) | (11,589) | (18,855) |
| Other (expense) income: | ||||
| Interest expense | (1,982) | (1,898) | (3,959) | (3,583) |
| Change in fair value of warrant liability, net | — | 98 | — | (280) |
| Other income, net | 97 | 51 | 482 | 149 |
| Total other expense | (1,885) | (1,749) | (3,477) | (3,714) |
| Net loss | $(7,273) | $(11,468) | $(15,066) | $(22,569) |
| Net loss per share, basic and diluted | $(0.71) | $(1.56) | $(1.51) | $(3.08) |
| Weighted-average shares outstanding, basic and diluted | 10,296 | 7,333 | 9,977 | 7,316 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.